MacroGenics and Takeda agreed to co-develop four product candidates using the biotech's Dual-Affinity Re-Targeting (DART) platform. MacroGenics, located in Rockville, Maryland, has created over 100 DART molecules, which target multiple antigens or cells using a single, antibody-like molecule. The recent $400-million deal includes four DART-based product candidates for autoimmune disorders. This is Takeda's second alliance with MacroGenics this year. The first was in May when Osaka, Japan–based Takeda licensed MGD010, a bispecific antibody against CD32B and CD79B, following a phase 1a trial in an autoimmune disorder.
Rights and permissions
About this article
Cite this article
Takeda's second bet on DARTs. Nat Biotechnol 32, 1070 (2014). https://doi.org/10.1038/nbt1114-1070a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1114-1070a